Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
This page contains content from the copyrighted Wikipedia article "Mozavaptan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
